{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T20:46:46Z","timestamp":1780606006078,"version":"3.54.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1007\/s12185-020-03042-1","type":"journal-article","created":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T19:02:32Z","timestamp":1609527752000},"page":"413-421","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Long-term safety and efficacy of imatinib in pediatric patients with chronic myeloid leukemia: single-center experience from China"],"prefix":"10.1007","volume":"113","author":[{"given":"Yuli","family":"Cai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,1]]},"reference":[{"key":"3042_CR1","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1542\/peds.2004-2473","volume":"116","author":"F Millot","year":"2005","unstructured":"Millot F, Traore P, Guilhot J, Nelken B, Leblanc T, Leverger G, et al. Clinical and biological features at diagnosis in 40 children with chronic myeloid leukemia. Pediatrics. 2005;116:140\u20133.","journal-title":"Pediatrics"},{"key":"3042_CR2","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391\u2013405.","journal-title":"Blood"},{"key":"3042_CR3","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.pcl.2014.09.008","volume":"62","author":"N Hijiya","year":"2015","unstructured":"Hijiya N, Millot F, Suttorp M. Chronic myeloid leukemia in children: clinical findings, management, and unanswered questions. Pediatr Clin N Am. 2015;62:107\u201319.","journal-title":"Pediatr Clin N Am"},{"key":"3042_CR4","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1038\/s41375-018-0179-9","volume":"32","author":"M Suttorp","year":"2018","unstructured":"Suttorp M, Schulze P, Glauche I, Gohring G, von Neuhoff N, Metzler M, et al. Front-line imatinib treatment in children and adolescents with chronic myeloid leukemia: results from a phase III trial. Leukemia. 2018;32:1657\u201369.","journal-title":"Leukemia"},{"key":"3042_CR5","doi-asserted-by":"publisher","first-page":"2430","DOI":"10.3109\/10428194.2012.694076","volume":"53","author":"KC Lakshmaiah","year":"2012","unstructured":"Lakshmaiah KC, Bhise R, Purohit S, Abraham LJ, Lokanatha D, Suresh TM, et al. Chronic myeloid leukemia in children and adolescents: results of treatment with imatinib mesylate. Leukemia Lymphoma. 2012;53:2430\u20133.","journal-title":"Leukemia Lymphoma"},{"key":"3042_CR6","doi-asserted-by":"publisher","first-page":"2827","DOI":"10.1200\/JCO.2010.32.7114","volume":"29","author":"F Millot","year":"2011","unstructured":"Millot F, Baruchel A, Guilhot J, Petit A, Leblanc T, Bertrand Y, et al. Imatinib is effective in children with previously untreated chronic myelogenous leukemia in early chronic phase: results of the French national phase IV trial. J Clin Oncol. 2011;29:2827\u201332.","journal-title":"J Clin Oncol"},{"key":"3042_CR7","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1093\/annonc\/mdu490","volume":"26","author":"F Castagnetti","year":"2015","unstructured":"Castagnetti F, Gugliotta G, Baccarani M, Breccia M, Specchia G, Levato L, et al. Differences among young adults, adults and elderly chronic myeloid leukemia patients. Ann Oncol. 2015;26:185\u201392.","journal-title":"Ann Oncol"},{"key":"3042_CR8","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1182\/blood-2011-10-380774","volume":"119","author":"JR Andolina","year":"2012","unstructured":"Andolina JR, Neudorf SM, Corey SJ. How I treat childhood CML. Blood. 2012;119:1821\u201330.","journal-title":"Blood"},{"key":"3042_CR9","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1007\/s00277-015-2367-2","volume":"94","author":"D Gurrea Salas","year":"2015","unstructured":"Gurrea Salas D, Glauche I, Tauer JT, Thiede C, Suttorp M. Can prognostic scoring systems for chronic myeloid leukemia as established in adults be applied to pediatric patients? Ann Hematol. 2015;94:1363\u201371.","journal-title":"Ann Hematol"},{"key":"3042_CR10","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1182\/blood-2015-06-648667","volume":"127","author":"N Hijiya","year":"2016","unstructured":"Hijiya N, Schultz KR, Metzler M, Millot F, Suttorp M. Pediatric chronic myeloid leukemia is a unique disease that requires a different approach. Blood. 2016;127:392\u20139.","journal-title":"Blood"},{"key":"3042_CR11","doi-asserted-by":"publisher","first-page":"3206","DOI":"10.1016\/j.ejca.2014.10.007","volume":"50","author":"F Millot","year":"2014","unstructured":"Millot F, Guilhot J, Baruchel A, Petit A, Leblanc T, Bertrand Y, et al. Growth deceleration in children treated with imatinib for chronic myeloid leukaemia. Eur J Cancer. 2014;50:3206\u201311.","journal-title":"Eur J Cancer"},{"key":"3042_CR12","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.jpeds.2011.03.046","volume":"159","author":"H Shima","year":"2011","unstructured":"Shima H, Tokuyama M, Tanizawa A, Tono C, Hamamoto K, Muramatsu H, et al. Distinct impact of imatinib on growth at prepubertal and pubertal ages of children with chronic myeloid leukemia. J Pediatr. 2011;159:676\u201381.","journal-title":"J Pediatr"},{"key":"3042_CR13","doi-asserted-by":"publisher","unstructured":"Samis J, Lee P, Zimmerman D, Suttorp M, Hijiya N. The complexity of growth failure in children receiving tyrosine kinase inhibitor therapy for chronic myelogenous leukemia. Pediatr Blood Cancer. 2017;64. https:\/\/doi.org\/10.1002\/pbc.26703","DOI":"10.1002\/pbc.26703"},{"key":"3042_CR14","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","volume":"11","author":"F-X Mahon","year":"2010","unstructured":"Mahon F-X, R\u00e9a D, Guilhot J, Guilhot F, Huguet F, Nicolini F, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010;11:1029\u201335.","journal-title":"Lancet Oncol"},{"key":"3042_CR15","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S1470-2045(18)30192-X","volume":"19","author":"S Saussele","year":"2018","unstructured":"Saussele S, Richter J, Guilhot J, Gruber FX, Hjorth-Hansen H, Almeida A, et al. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncol. 2018;19:747\u201357.","journal-title":"Lancet Oncol"},{"key":"3042_CR16","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.6004\/jnccn.2018.0071","volume":"16","author":"JP Radich","year":"2018","unstructured":"Radich JP, Deininger M, Abboud CN, Altman JK, Berman E, Bhatia R, et al. Chronic myeloid leukemia, version 1. 2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2018;16:1108\u201335.","journal-title":"J Natl Compr Canc Netw."},{"key":"3042_CR17","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122:872\u201384.","journal-title":"Blood"},{"key":"3042_CR18","doi-asserted-by":"publisher","first-page":"e59569","DOI":"10.1371\/journal.pone.0059569","volume":"8","author":"XN Zong","year":"2013","unstructured":"Zong XN, Li H. Construction of a new growth references for China based on urban Chinese children: comparison with the WHO growth standards. PLoS ONE. 2013;8:e59569.","journal-title":"PLoS ONE"},{"issue":"6","key":"3042_CR19","first-page":"622","volume":"26","author":"XL Kong","year":"2018","unstructured":"Kong XL, Xiao SP, Huang XH, et al. Quantitative analysis of height and weight in children with beta-thalassemia major and the associated factor [J]. Chin J Child Health Care. 2018;26(6):622\u20135.","journal-title":"Chin J Child Health Care"},{"key":"3042_CR20","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1200\/JCO.2017.75.9597","volume":"36","author":"L Gore","year":"2018","unstructured":"Gore L, Kearns PR, de Martino ML, Lee N, De Souza CA, Bertrand Y, et al. Dasatinib in pediatric patients with chronic myeloid leukemia in chronic phase: results from a phase II trial. J Clin Oncol. 2018;36:1330\u20138.","journal-title":"J Clin Oncol."},{"key":"3042_CR21","doi-asserted-by":"publisher","first-page":"2374","DOI":"10.1182\/blood.2018882233","volume":"133","author":"N Hijiya","year":"2019","unstructured":"Hijiya N, Suttorp M. How I treat chronic myeloid leukemia in children and adolescents. Blood. 2019;133:2374\u201384.","journal-title":"Blood"},{"key":"3042_CR22","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1111\/ped.12876","volume":"58","author":"A Tanizawa","year":"2016","unstructured":"Tanizawa A. Optimal management for pediatric chronic myeloid leukemia. Pediatr Int. 2016;58:171\u20139.","journal-title":"Pediatr Int"},{"key":"3042_CR23","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.3109\/10428194.2012.745525","volume":"54","author":"Y Chen","year":"2013","unstructured":"Chen Y, Wang H, Kantarjian H, Cortes J. Trends in chronic myeloid leukemia incidence and survival in the United States from 1975 to 2009. Leuk Lymphoma. 2013;54:1411\u20137.","journal-title":"Leuk Lymphoma"},{"key":"3042_CR24","first-page":"35","volume":"39","author":"YM Shi","year":"2015","unstructured":"Shi YM, Liu S. Sex ratio at birth in China: changes and implications [J]. Popul Res. 2015;39:35\u201348.","journal-title":"Popul Res"},{"key":"3042_CR25","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1182\/blood-2002-12-3637","volume":"102","author":"K Cwynarski","year":"2003","unstructured":"Cwynarski K, Roberts IAG, Iacobelli S, van Biezen A, Brand R, Devergie A, et al. Stem cell transplantation for chronic myeloid leukemia in children. Blood. 2003;102:1224\u201331.","journal-title":"Blood"},{"key":"3042_CR26","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1002\/ajh.21380","volume":"84","author":"C Pavlovsky","year":"2009","unstructured":"Pavlovsky C, Kantarjian H, Cortes JE. First-line therapy for chronic myeloid leukemia: past, present, and future. Am J Hematol. 2009;84:287\u201393.","journal-title":"Am J Hematol"},{"issue":"67","key":"3042_CR27","first-page":"183","volume":"2016","author":"MA Karalexi","year":"1990","unstructured":"Karalexi MA, Baka M, Ryzhov A, Zborovskaya A, Dimitrova N, Zivkovic S, et al. Survival trends in childhood chronic myeloid leukaemia in Southern-Eastern Europe and the United States of America. Eur J Cancer Oxf Engl. 1990;2016(67):183\u201390.","journal-title":"Eur J Cancer Oxf Engl"},{"key":"3042_CR28","first-page":"227","volume":"22","author":"MS El-Alfy","year":"2010","unstructured":"El-Alfy MS, Al-Haddad AM, Hamed AA. Management of CML in the pediatric age group: imatinib mesylate or SCT. J Egypt Natl Canc Inst. 2010;22:227\u201332.","journal-title":"J Egypt Natl Canc Inst"},{"key":"3042_CR29","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1111\/bjh.13453","volume":"170","author":"F Giona","year":"2015","unstructured":"Giona F, Putti MC, Micalizzi C, Menna G, Moleti ML, Santoro N, et al. Long-term results of high-dose imatinib in children and adolescents with chronic myeloid leukaemia in chronic phase: the Italian experience. Br J Haematol. 2015;170:398\u2013407.","journal-title":"Br J Haematol"},{"key":"3042_CR30","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1007\/s12098-015-2007-9","volume":"83","author":"RR Ganta","year":"2016","unstructured":"Ganta RR, Nasaka S, Gundeti S. Impact of imatinib adherence on the cytogenetic response in pediatric chronic myeloid leukemia\u2014chronic phase. Indian J Pediatr. 2016;83:1009\u201312.","journal-title":"Indian J Pediatr"},{"key":"3042_CR31","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1111\/bjh.14458","volume":"180","author":"F Giona","year":"2018","unstructured":"Giona F, Saglio G, Santopietro M, Menna G, Putti MC, Micalizzi C, et al. Early response does not predict outcome in children and adolescents with chronic myeloid leukaemia treated with high-dose imatinib. Br J Haematol. 2018;180:895\u20138.","journal-title":"Br J Haematol"},{"key":"3042_CR32","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1038\/leu.2016.34","volume":"30","author":"E Nievergall","year":"2016","unstructured":"Nievergall E, Reynolds J, Kok CH, Watkins DB, Biondo M, Busfield SJ, et al. TGF-\u03b1 and IL-6 plasma levels selectively identify CML patients who fail to achieve an early molecular response or progress in the first year of therapy. Leukemia. 2016;30:1263\u201372.","journal-title":"Leukemia"},{"key":"3042_CR33","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1182\/bloodadvances.2019000195","volume":"3","author":"CH Kok","year":"2019","unstructured":"Kok CH, Yeung DT, Lu L, Watkins DB, Leclercq TM, Dang P, et al. Gene expression signature that predicts early molecular response failure in chronic-phase CML patients on frontline imatinib. Blood Adv. 2019;3:1610\u201321.","journal-title":"Blood Adv"},{"key":"3042_CR34","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1056\/NEJMoa1609324","volume":"376","author":"A Hochhaus","year":"2017","unstructured":"Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017;376:917\u201327.","journal-title":"N Engl J Med"},{"key":"3042_CR35","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/bjh.12977","volume":"167","author":"J de la Fuente","year":"2014","unstructured":"de la Fuente J, Baruchel A, Biondi A, de Bont E, Dresse MF, Suttorp M, et al. Managing children with chronic myeloid leukaemia (CML): recommendations for the management of CML in children and young people up to the age of 18 years. Br J Haematol. 2014;167:33\u201347.","journal-title":"Br J Haematol"},{"key":"3042_CR36","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"BJ Druker","year":"2006","unstructured":"Druker BJ, Guilhot F, O\u2019Brien SG, Gathmann I, Kantarjian H, Gattermann N, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408\u201317.","journal-title":"N Engl J Med"},{"key":"3042_CR37","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1002\/pbc.26028","volume":"63","author":"J Samis","year":"2016","unstructured":"Samis J, Lee P, Zimmerman D, Arceci RJ, Suttorp M, Hijiya N. Recognizing endocrinopathies associated with tyrosine kinase inhibitor therapy in children with chronic myelogenous leukemia. Pediatr Blood Cancer. 2016;63:1332\u20138.","journal-title":"Pediatr Blood Cancer"},{"key":"3042_CR38","doi-asserted-by":"publisher","first-page":"4947","DOI":"10.1182\/blood.V90.12.4947","volume":"90","author":"M Carroll","year":"1997","unstructured":"Carroll M, Ohno-Jones S, Tamura S, Buchdunger E, Zimmermann J, Lydon NB, et al. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood. 1997;90:4947\u201352.","journal-title":"Blood"},{"key":"3042_CR39","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1002\/pbc.24397","volume":"60","author":"KR Narayanan","year":"2013","unstructured":"Narayanan KR, Bansal D, Walia R, Sachdeva N, Bhansali A, Varma N, et al. Growth failure in children with chronic myeloid leukemia receiving imatinib is due to disruption of GH\/IGF-1 axis. Pediatr Blood Cancer. 2013;60:1148\u201353.","journal-title":"Pediatr Blood Cancer"},{"key":"3042_CR40","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1002\/pbc.23389","volume":"59","author":"D Bansal","year":"2012","unstructured":"Bansal D, Shava U, Varma N, Trehan A, Marwaha RK. Imatinib has adverse effect on growth in children with chronic myeloid leukemia. Pediatr Blood Cancer. 2012;59:481\u20134.","journal-title":"Pediatr Blood Cancer"},{"key":"3042_CR41","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1002\/pbc.24121","volume":"59","author":"MV Rastogi","year":"2012","unstructured":"Rastogi MV, Stork L, Druker B, Blasdel C, Nguyen T, Boston BA. Imatinib mesylate causes growth deceleration in pediatric patients with chronic myelogenous leukemia. Pediatr Blood Cancer. 2012;59:840\u20135.","journal-title":"Pediatr Blood Cancer"},{"key":"3042_CR42","doi-asserted-by":"publisher","first-page":"e25","DOI":"10.3324\/haematol.2012.067447","volume":"98","author":"F Giona","year":"2013","unstructured":"Giona F, Mariani S, Gnessi L, Moleti ML, Rea M, De Vellis A, et al. Bone metabolism, growth rate and pubertal development in children with chronic myeloid leukemia treated with imatinib during puberty. Haematologica. 2013;98:e25-27.","journal-title":"Haematologica"},{"key":"3042_CR43","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1111\/bjh.15826","volume":"185","author":"CMA de Bruijn","year":"2019","unstructured":"de Bruijn CMA, Millot F, Suttorp M, Borisevich M, Brons P, Lausen B, et al. Discontinuation of imatinib in children with chronic myeloid leukaemia in sustained deep molecular remission: results of the STOP IMAPED study. Br J Haematol. 2019;185:718\u201324.","journal-title":"Br J Haematol"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-020-03042-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-020-03042-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-020-03042-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T05:43:02Z","timestamp":1674798182000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-020-03042-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,1]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["3042"],"URL":"https:\/\/doi.org\/10.1007\/s12185-020-03042-1","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,1]]},"assertion":[{"value":"8 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 January 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}